For the Inventor, By the Inventor

Enter assignee name

Berkeley, CA, United States of America

Xoma Corporation

USPTO Granted Patents = 142

% Expired Patents = 2.8

CIPO Patents = 3

EPO Patents = 7

Forward Citations = 4,471

Loading Chart...

Loading Chart...

76 inventors (with patents filed for the assignee):

Roger G Little, Ii (25 out of 36 patents)

Stephen Fitzhugh Carroll (24 out of 30 patents)

Arnold H Horwitz (23 out of 49 patents)

4. Marc D Better (20 out of 29 patents)

5. Lewis H Lambert, Jr (16 out of 16 patents)

6. Patrick J Scannon (14 out of 30 patents)

7. Mark Leslie White (13 out of 33 patents)

8. Lynn S Grinna (13 out of 15 patents)

9. Randy R Robinson (13 out of 18 patents)

10. William Steve Ammons (11 out of 11 patents)

11. Shau-Ping Lei (11 out of 14 patents)

12. Gary L Wilcox (11 out of 14 patents)

13. Georgia Theofan (10 out of 12 patents)

14. Alvin Y Liu (10 out of 14 patents)

15. Gary M Studnicka (9 out of 11 patents)

Core Competencies:

Bactericidal Proteins

Therapeutic Compositions

Anti-Fungal Peptides

Immunotoxins

Antithrombotic Materials

Mycobacterial Diseases

Recombinant Microbial Production

Lipopolysaccharide Binding Proteins

Biologically Active Peptides

Chlamydial Treatments

Gram-Negative Infections

Fusion Proteins

142 patents: Sort by Forward Citations

1. 7081334 - Method for quantifying LBP in body fluids (2006-07-25),

2. 6849598 - Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products (2005-02-01),

3. 6828418 - Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same (2004-12-07),

4. 6767893 - Method of treating conditions associated with intestinal ischemia/reperfusion (2004-07-27),

5. 6759203 - Method for quantifying BPI in body fluids (2004-07-06),

6. 6686332 - Method of treating depressed reticuloendothelial system function (2004-02-03),

7. 6664231 - Anti-fungal peptides (2003-12-16),

8. 6620785 - Treatment of Mycobacterial diseases by administration of bactericidal/permeability-increasing protein products (2003-09-16),

9. 6599881 - Antithrombotic materials and methods (2003-07-29),

10. 6599880 - Bactericidal/permeability-increasing protein (BPI) deletion analogs (2003-07-29),

11. 6596691 - Therapeutic uses of BPI protein products for human meningococcemia (2003-07-22),

12. 6586400 - Human therapeutic uses of BPI protein products (2003-07-01),

13. 6583116 - Anti-chlamydial methods and materials (2003-06-24),

14. 6482796 - Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients (2002-11-19),

15. 6440936 - Anti-protozoan methods and materials (2002-08-27),

Company Overview

Xoma Corporation, based in Berkeley, California, specializes in the development of innovative bactericidal protein products aimed at addressing various medical challenges. The company focuses on therapeutic compositions that include anti-fungal peptides, immunotoxins, and antithrombotic materials, contributing to advancements in the treatment of mycobacterial diseases. Leveraging recombinant microbial production techniques, Xoma is dedicated to enhancing the efficacy of its products while exploring the potential of lipopolysaccharide binding proteins in therapeutic applications.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

142 Patents

#2 in Berkeley, CA

#608 in California

#2,750 in US

#5,717 in the World

Berkeley, CA, United States of America

Xoma Corporation

Forward Citations = 4,471

76 inventors:

Roger G Little, Ii (25 out of 36 patents)

Stephen Fitzhugh Carroll (24 out of 30 patents)

Arnold H Horwitz (23 out of 49 patents)

4. Marc D Better (20 out of 29 patents)

5. Lewis H Lambert, Jr (16 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Xoma Corporation. Retrieved from https://idiyas.com/company/xoma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…